Britain's state health service has advised against paying for Pfizer's inhaled insulin Exubera, saying that the therapy isn't worth the added cost. Pfizer called the decision "perverse and short-sighted." Article
Click here to get the FierceBiotech email newsletter for FREE!
Click here to get the FierceBiotech email newsletter for FREE!